Pancreatic Cancer
Conditions
Keywords
stage IB pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, adenocarcinoma of the pancreas
Brief summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, epirubicin hydrochloride, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether gemcitabine hydrochloride is more effective when given alone or together with combination chemotherapy and radiation therapy in treating patients with pancreatic cancer. PURPOSE: This randomized phase II/III trial is studying gemcitabine hydrochloride to see how well it works when given alone or together with combination chemotherapy and radiation therapy in treating patients with stage IB, stage II, or stage III pancreatic cancer.
Detailed description
OBJECTIVES: Primary * Assess the 1-year progression-free survival of patients with stage IB, II, or III adenocarcinoma of the pancreas treated with adjuvant therapy comprising gemcitabine with vs without cisplatin, epirubicin hydrochloride, and fluorouracil followed by chemoradiotherapy with fluorouracil or capecitabine. (Phase II) * Compare the 2-year overall survival of patients treated with these regimens. (Phase III) Secondary * Assess the feasibility and toxicity of these regimens in these patients. * Assess the impact of these regimens on the quality of life of these patients. * Assess the pattern of relapse in patients treated with these regimens. OUTLINE: This is a multicenter study. Patients are stratified according to participating center and radical surgery. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-4 weeks after the completion of chemotherapy, patients in both arms undergo radiotherapy 5 days a week for 6 weeks. Patients also receive concurrent fluorouracil IV continuously or oral capecitabine during radiotherapy. After completion of study treatment, patients are followed up every 3 months.
Interventions
DRUGcapecitabine
Given orally
DRUGcisplatin
Given IV
DRUGepirubicin hydrochloride
Given IV
DRUGfluorouracil
Given IV
DRUGgemcitabine hydrochloride
Given IV
Sponsors
IRCCS San Raffaele
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the pancreas * Stage IB-III disease * Has undergone surgery with radical intent (R0 or R1) within the past 2 months PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% (90-100% for patients 71-75 years of age) * WBC ≥ 3,500/mm\^3 * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL * Creatinine ≤ 1.5 mg/dL * Bilirubin ≤ 2 mg/dL * SGOT and SGPT ≤ 2 times upper limit of normal * Not pregnant or nursing * No other malignancy within the past 5 years except surgically treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin * No psychological, familial, sociological, or geographical condition that would potentially hinder study compliance or follow-up schedule PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy or radiotherapy for pancreatic adenocarcinoma * No other concurrent experimental drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year progression-free survival (Phase II) | every 3 months during the first 2 years, every 6 months afterwards |
Secondary
| Measure | Time frame |
|---|---|
| Pattern of relapse | every 3 months during the first 2 years, every 6 months afterwards |
Countries
Italy
Outcome results
None listed